(AOF) – Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary probe and needle laser confocal endomicroscopy platform, announces that the Combined General Meeting of Shareholders has approved the plan to transfer the listing of its shares from the regulated market Euronext Paris compartment C, to the Euronext Growth Paris market The Board of Directors held following the Combined General Meeting of June 8, 2023 decided to implement this transfer.
Subject to the agreement of Euronext Paris, the listing of the Company’s shares on Euronext Growth Paris will take place within the framework of an accelerated procedure for the admission to trading of the existing shares of the company, without the issuance of shares. news.
“The decision to transfer our listing to Euronext Growth is only natural, as this market is now perfectly suited to the size and growth profile of the Company. We will thus benefit from a solid and expanding market place to attract new investors. This decision is also economical, as it will allow us to reduce certain administrative costs and allocate our resources to value-creating activities,” said Sacha Loiseau, Chairman and CEO of Mauna Kea Technologies. “At the same time, we will maintain regular and equally transparent communication, maintaining the same standards and frequencies of financial publication.”
AOF – LEARN MORE
Find out more about the “pharmacy” sector
Loss of speed in European research
European research is losing ground to American and Chinese research. In twenty years, Europe’s share has fallen from 41% to 31% in global R&D. China’s share jumped from 1% to 8%. As for the United States, which supplanted Europe, in 2001 it devoted only 2 billion euros per year more than Europe to R&D, whereas now this gap has reached 25 billion! Some experts accuse the European authorities of not having deployed effective policies. The financing of pharmaceutical research should therefore have been better targeted via the “Horizon 2020” programme. France only comes in eighteenth position in European funding despite the quality of its research. Conversely, the United States concentrates funding on Boston and a few centers of excellence.